A new lawsuit has joined numerous others against Jannsen Pharmaceuticals, the makers of the popular anticoagulant Xarelto.

Plaintiff Harry K. of Texas filed the Xarelto lawsuit, alleging that Xarelto is inherently more dangerous than other drugs of its type, leading to life-threatening medical complications.

Xarelto is an anticoagulant, or blood thinner, that prevents dangerous blood clots. All anticoagulants carry some risk, but plaintiffs in Xarelto lawsuits claim that Xarelto carries the risk of working too well.

When this happens, the body cannot form blood clots to stop the bleeding and patients are at risk of serious injury from uncontrollable bleeding.

In severe cases, a patient can bleed to death from very minor injuries, including tiny internal injuries common in the lungs and GI tract.

Xarelto Lawsuit

Harry’s Xarelto lawsuit explains how his physicians prescribed him Xarelto in 2013. Shortly after, he found himself in the hospital with a life-threatening case of pulmonary bleeding. The bleeding caused Harry severe pain and suffering, required expensive medical care, and interfered with his income.

A key allegation of Harry’s Xarelto lawsuit is that the drug is inherently defective and more dangerous than other anticoagulants. The Xarelto lawsuit further alleges that it is fraudulently promoted as safer than other anticoagulants on the market.

One of the big differences between Xarelto and older anticoagulants is the lack of a reversal agent. If a patient taking an older anticoagulant like Warfarin experience pulmonary bleeding or other types of uncontrollable bleeding, doctors can use a second drug, the reversal agent, to effectively shut down the anticoagulant.

Unlike older, off-patent anticoagulants, Xarelto has no known reversal agent. Harry K’s Xarelto lawsuit holds that this makes Xarelto more dangerous than similar drugs on the market, and to promote its use, the lawsuit alleges, is criminally fraudulent.

So many Xarelto lawsuits have been filed that the court system has resorted to a process called multidistrict litigation, or MDL, to coordinate them. In MDL, similar cases are grouped together and coordinated to avoid duplication of costly efforts.

Since Xarelto lawsuits typically hinge on similar evidence and make similar accusations against the makers of Xarelto, these lawsuits are ideal for inclusion in a single Xarelto MDL.

The Xarelto Lawsuit is Harry K. vs. Janssen Research & Development, LLC, et al, case No. 1753, within the larger Xarelto MDL In Re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL No. 2592, filed in the U.S. District Court for the Eastern District of Louisiana.